HRP20040371B1 - Thiopene- amd thiazolesulfonamides as antineoplastic agents - Google Patents

Thiopene- amd thiazolesulfonamides as antineoplastic agents

Info

Publication number
HRP20040371B1
HRP20040371B1 HRP20040371AA HRP20040371A HRP20040371B1 HR P20040371 B1 HRP20040371 B1 HR P20040371B1 HR P20040371A A HRP20040371A A HR P20040371AA HR P20040371 A HRP20040371 A HR P20040371A HR P20040371 B1 HRP20040371 B1 HR P20040371B1
Authority
HR
Croatia
Prior art keywords
alkyl
halogen
thiazolesulfonamides
thiopene
amd
Prior art date
Application number
HRP20040371AA
Other languages
English (en)
Croatian (hr)
Inventor
Alfonso@De@Dios
Cora@Sue@Grossman
Philip@Arthur@Hipskind
Ho@Shen@Lin
Karen@Lynn@Lobb
Beatriz@L�pez@de@Uralde@Garmendia
Jose@Eduardo@Lopez
Mary@Margaret@Mader
Michael@Enrico@Richett
Chuan@Shih
Original Assignee
Eli@Lilly@and@Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli@Lilly@and@Company filed Critical Eli@Lilly@and@Company
Publication of HRP20040371A2 publication Critical patent/HRP20040371A2/hr
Publication of HRP20040371B1 publication Critical patent/HRP20040371B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HRP20040371AA 2001-10-25 2004-04-26 Thiopene- amd thiazolesulfonamides as antineoplastic agents HRP20040371B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35201201P 2001-10-25 2001-10-25
PCT/US2002/031568 WO2003035629A1 (en) 2001-10-25 2002-10-15 Thiopene- amd thiazolesulfonamides as antineoplastic agents

Publications (2)

Publication Number Publication Date
HRP20040371A2 HRP20040371A2 (en) 2004-08-31
HRP20040371B1 true HRP20040371B1 (en) 2012-07-31

Family

ID=23383421

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040371AA HRP20040371B1 (en) 2001-10-25 2004-04-26 Thiopene- amd thiazolesulfonamides as antineoplastic agents

Country Status (34)

Country Link
US (2) US7084170B2 (ru)
EP (1) EP1442030B1 (ru)
JP (1) JP4464681B2 (ru)
KR (1) KR100913471B1 (ru)
CN (1) CN1298709C (ru)
AR (1) AR037248A1 (ru)
AT (1) ATE338033T1 (ru)
AU (1) AU2002334817B2 (ru)
BR (1) BR0212386A (ru)
CA (1) CA2463300C (ru)
CY (1) CY1106247T1 (ru)
DE (1) DE60214413T2 (ru)
DK (1) DK1442030T3 (ru)
EA (1) EA006081B1 (ru)
EC (1) ECSP045078A (ru)
EG (1) EG26021A (ru)
ES (1) ES2269816T3 (ru)
HK (1) HK1068337A1 (ru)
HR (1) HRP20040371B1 (ru)
HU (1) HUP0401638A3 (ru)
IL (2) IL160851A0 (ru)
MX (1) MXPA04003886A (ru)
MY (1) MY130718A (ru)
NO (1) NO20041316L (ru)
NZ (1) NZ531136A (ru)
PE (1) PE20030574A1 (ru)
PL (1) PL208083B1 (ru)
PT (1) PT1442030E (ru)
SI (1) SI1442030T1 (ru)
SV (1) SV2004001367A (ru)
TW (1) TWI281916B (ru)
UA (1) UA75716C2 (ru)
WO (1) WO2003035629A1 (ru)
ZA (1) ZA200403089B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100900304B1 (ko) * 2001-06-11 2009-06-02 바이로켐 파마 인코포레이티드 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
JP2005531608A (ja) * 2002-06-06 2005-10-20 スミスクライン・ビーチャム・コーポレイション NF−κB阻害剤
ES2345438T3 (es) * 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2006030947A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JPWO2006090928A1 (ja) * 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の血管新生阻害物質との新規併用
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
JPWO2006090930A1 (ja) * 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の新規併用
CN101218224B (zh) 2005-05-13 2013-05-08 Viro化学制药公司 治疗或预防黄病毒感染的组合物和方法
US7208506B2 (en) 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
WO2007123274A1 (ja) 2006-04-20 2007-11-01 Eisai R & D Management Co., Ltd. スルホンアミド化合物の新規感受性マーカー
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
JP5290186B2 (ja) 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
WO2008138594A1 (en) 2007-05-16 2008-11-20 F. Hoffmann-La Roche Ag Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CN101899008B (zh) * 2010-05-20 2012-10-17 中国人民解放军第二军医大学 N-取代嘧啶磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN103450149B (zh) * 2012-06-01 2015-10-14 中国科学院上海有机化学研究所 苯基噻吩磺酰胺类化合物及其制备方法和用途
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
CN106588868A (zh) * 2016-11-16 2017-04-26 武汉理工大学 一种2‑溴‑3‑噻吩甲酸中间体的合成方法
CN108558822B (zh) * 2018-06-01 2020-12-18 盐城锦明药业有限公司 N-((5-溴噻吩-2-基)磺酰基)-2,4-二氯苯甲酰胺的合成方法
CN110835345A (zh) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN109265437A (zh) * 2018-10-19 2019-01-25 凯莱英医药集团(天津)股份有限公司 一种3-羟基噻吩-2-羧酸酯类化合物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513979A1 (en) * 1991-03-26 1992-11-19 Merck & Co. Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
EP0560554A2 (en) * 1992-03-13 1993-09-15 Eli Lilly And Company Antitumor compositions and methods of treatment
US5302724A (en) * 1990-07-17 1994-04-12 Eli Lilly And Company Antitumor compositions and methods of treatment
WO1998014440A1 (en) * 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
DE69734734D1 (de) * 1996-07-05 2005-12-29 Us Gov Health & Human Serv Gesättigte 1,2-dithiaheterocyclische verbindungen enthaltende antivirale pharmazeutische zubereitungen
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302724A (en) * 1990-07-17 1994-04-12 Eli Lilly And Company Antitumor compositions and methods of treatment
EP0513979A1 (en) * 1991-03-26 1992-11-19 Merck & Co. Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
EP0560554A2 (en) * 1992-03-13 1993-09-15 Eli Lilly And Company Antitumor compositions and methods of treatment
WO1998014440A1 (en) * 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment

Also Published As

Publication number Publication date
IL160851A0 (en) 2004-08-31
JP4464681B2 (ja) 2010-05-19
ECSP045078A (es) 2004-06-28
DE60214413D1 (de) 2006-10-12
NO20041316L (no) 2004-03-30
CY1106247T1 (el) 2011-06-08
NZ531136A (en) 2006-08-31
AU2002334817B2 (en) 2008-02-21
JP2005511547A (ja) 2005-04-28
CA2463300A1 (en) 2003-05-01
ZA200403089B (en) 2005-04-22
AR037248A1 (es) 2004-11-03
MY130718A (en) 2007-07-31
EG26021A (en) 2012-12-10
HK1068337A1 (en) 2005-04-29
US7084170B2 (en) 2006-08-01
CN1575286A (zh) 2005-02-02
PE20030574A1 (es) 2003-07-03
PL368234A1 (en) 2005-03-21
CA2463300C (en) 2011-07-19
TWI281916B (en) 2007-06-01
CN1298709C (zh) 2007-02-07
US20040198784A1 (en) 2004-10-07
WO2003035629A1 (en) 2003-05-01
ATE338033T1 (de) 2006-09-15
HRP20040371A2 (en) 2004-08-31
EP1442030A1 (en) 2004-08-04
DE60214413T2 (de) 2007-03-08
PL208083B1 (pl) 2011-03-31
SI1442030T1 (sl) 2006-12-31
EA200400582A1 (ru) 2004-08-26
IL160851A (en) 2009-11-18
EP1442030B1 (en) 2006-08-30
DK1442030T3 (da) 2006-12-27
US7250430B2 (en) 2007-07-31
US20060223871A1 (en) 2006-10-05
UA75716C2 (en) 2006-05-15
PT1442030E (pt) 2006-12-29
BR0212386A (pt) 2004-07-27
EA006081B1 (ru) 2005-08-25
ES2269816T3 (es) 2007-04-01
HUP0401638A3 (en) 2012-09-28
KR20040062583A (ko) 2004-07-07
MXPA04003886A (es) 2004-07-08
HUP0401638A2 (hu) 2004-11-29
SV2004001367A (es) 2004-02-24
KR100913471B1 (ko) 2009-08-25

Similar Documents

Publication Publication Date Title
HRP20040371B1 (en) Thiopene- amd thiazolesulfonamides as antineoplastic agents
DE60208364D1 (de) Chinolinderivate mit einer azolylgruppe und chinazolinderivate
HRP20020938B1 (en) Tropane derivatives useful in therapy
RS52119B (en) 4-phenylamino-HINAZOLIN-6-IL-STARCHES
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
SE0000540D0 (sv) New compounds
CA2436846A1 (en) Thioether substituted imidazoquinolines
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
RS53038B (en) OXADIAZOLA DERIVATIVE Activate Sphingosine-1-Phosphate (SIP)
MY140572A (en) Quinazolinone derivatives as parp inhibitors
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
ATE302775T1 (de) Carbolinderivate
ATE431827T1 (de) Phosphonocephem-verbindung
HRP20070529T3 (en) Imidazole derivatives as glutmate receptor antagonists
RS51545B (en) THIAZOL PIRAZOLOPIRAMIDINS AS ANTAGONISTS OF CRF1 RECEPTORS
ATE346067T1 (de) Carbolinderivate
RS50879B (sr) Kristalna natrijumova so telmisartana i njena primena kao angiotenzinskog antagonista
RS52427B (en) ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICALALLY ACCEPTABLE SALTS AND MIXTURES, AND THEIR USE
PT1181294E (pt) Novos derivados e analogos da galantamina
PT1242402E (pt) Novos compostos
GB0112810D0 (en) Pyrimidine derivatives
ATE287397T1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
ATE293961T1 (de) Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20121011

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20131015